GoldenGolden
Advanced Search
Mateon Therapeutics

Mateon Therapeutics

Mateon Therapeutics is a biopharmaceutical company that looks to develop anti-vascular therapeutics for patients with cancer and optical diseases

Mateon Therapeutics is a biopharmaceutical company that looks to develop anti-vascular therapeutics for patients with cancer and optical diseases. The company was founded in 1988 in San Francisco, California, United States.

The company is developing anti-angiogenic agents, of which, some are approved by the FDA and used globally to treat cancer, as well as vascular disrupting agents for the same purpose.

COVID-19

With the outbreak of COVID-19, Mateon Therapeutics has launched an antiviral response program to combat the disease caused by the novel coronavirus. They are exploring therapeutic and artificial intelligence platforms to develop new coronavirus treatments. They are also advancing their efforts to fight the virus and any rare tropical diseases that may come in the near future. Mateon Therapeutics claims to have discovered some antiviral candidates and has partnered with researchers to further the progress of these candidates.

The company has also established a division for the approach of developing COVID-19 treatments as well as other future zootonic outbreaks.

Timeline

People

Name
Role
LinkedIn

Clint Webb

James Murphy

CFO

William Schwieterman

President, CEO

Further reading

Title
Author
Link
Type
Date

COVID-19 - Oncotelic Inc- a TGF ImmunoOncology Company

Web

Mateon launches antiviral programme focussed on Covid-19

Web

March 3, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Mateon Therapeutics

William Schwieterman

San Francisco, California, United States

Biotechnology, therapeutics

News

Title
Author
Date
Publisher
Description
BioSpace
June 10, 2020
BioSpace
The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of its first milestone and milestone payment by Autotelic BIO. OT-101 and IL-2 demonstrated good synergy against tumor xenograft model as an immune-oncology therapy. OT-101/IL-2 combination will advance to Phase 1 clinical development. AGOURA HILLS, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Mateo
BioSpace
June 1, 2020
BioSpace
Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Fatih M. Uckun, Vuong Trieu. Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated Kawasaki Disease in Children. Clin Res Pediatr 2020; 3(1): 1-3 Fatih M. Uckun, Larn Hwang, Vuong Trieu. Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ARDS in

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.